Editorial review: Medriva pages are written by named contributors, reviewed by clinical or subject-matter experts, and updated as evidence or regulatory status changes.

Huaxuan Launches Halal-Certified Bovine Collagen Peptides for Functional Beverages

Wednesday, June 24th, 2026 - Chinese ingredient manufacturer Huaxuan announced the launch of Halal-certified bovine collagen peptides intended for use in functional beverages, according to a company press release distributed via EINPresswire. The product is positioned for the sports nutrition and wellness beverage market.

The company said the bovine-derived collagen peptides are produced at its Xiamen, Fujian facility and have received Halal certification, which may expand their eligibility for use in products targeting Muslim-majority consumer markets. Huaxuan described the ingredient as suitable for "high-altitude desert" endurance applications, though the company did not provide specific clinical data supporting performance claims in the announcement.

Regulatory context remains separate from food ingredients

The announcement comes as regulatory scrutiny of peptide products continues to evolve. Unlike pharmaceutical-grade peptides subject to FDA oversight, collagen peptides marketed as food ingredients or dietary supplements fall under different regulatory frameworks. The FDA does not pre-approve food ingredients for safety or efficacy claims unless they are marketed as drugs.

Huaxuan's announcement did not indicate whether the product has undergone clinical trials or received FDA review for any specific health or performance claims.

Broader peptide landscape shows divergent regulatory paths

The launch follows recent FDA actions tightening rules on compounded GLP-1 drugs, including tirzepatide, after the agency declared the shortage resolved. Meanwhile, research continues on therapeutic peptides, including a Nature Metabolism study published Wednesday examining exercise combined with the GLP-1 receptor agonist liraglutide for cardiovascular outcomes beyond weight loss.

Related reading: For ongoing coverage of FDA actions on compounded GLP-1 drugs, see Medriva's /tracker/. For comparisons of regulated peptide therapies, see /compare/semaglutide-vs-tirzepatide/.